0M61 Stock Overview
A wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Myomo, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.60 |
| 52 Week High | US$5.06 |
| 52 Week Low | US$1.01 |
| Beta | 1.54 |
| 11 Month Change | 7.63% |
| 3 Month Change | 38.27% |
| 1 Year Change | 252.45% |
| 33 Year Change | -63.32% |
| 5 Year Change | -78.21% |
| Change since IPO | -98.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M61 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 6.0% | -3.7% | -1.9% |
| 1Y | 252.5% | 6.6% | 12.3% |
Return vs Industry: 0M61 exceeded the German Medical Equipment industry which returned 6.6% over the past year.
Return vs Market: 0M61 exceeded the German Market which returned 12.3% over the past year.
Price Volatility
| 0M61 volatility | |
|---|---|
| 0M61 Average Weekly Movement | 16.5% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0M61's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0M61's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 104 | Paul Gudonis | myomo.com |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device.
Myomo, Inc. Fundamentals Summary
| 0M61 fundamental statistics | |
|---|---|
| Market cap | €110.71m |
| Earnings (TTM) | -€8.61m |
| Revenue (TTM) | €19.23m |
5.8x
P/S Ratio-12.9x
P/E RatioIs 0M61 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M61 income statement (TTM) | |
|---|---|
| Revenue | US$21.11m |
| Cost of Revenue | US$6.89m |
| Gross Profit | US$14.22m |
| Other Expenses | US$23.66m |
| Earnings | -US$9.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 67.35% |
| Net Profit Margin | -44.75% |
| Debt/Equity Ratio | 0% |
How did 0M61 perform over the long term?
See historical performance and comparison